We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
E*TRADE (ETFC) Reports 9% Sequential Growth in October DARTs
Read MoreHide Full Article
E*TRADE Financial has reported a sequential rise in Daily Average Revenue Trades (DARTs) for October. According to its monthly market activity, the company’s DARTs came in at 290,578, up 9% from the previous month, but down 1% year over year. Notably, derivatives comprised 36% of DARTs.
Broker performance is generally measured through DARTs that represent the number of trades from which brokers can expect commission or fees. The rise in DARTs largely reflects investors’ willingness to invest in equity markets.
At the end of October 2019, E*TRADE’s total number of accounts were approximately 7.2 million, comprising about 5.1 million retail accounts, 1.9 million corporate services accounts, and 0.2 million advisor services accounts.
E*TRADE’s total accounts included 13,535 net reductions for October. Total brokerage accounts highlight the company’s ability to gain and retain customers who trade and invest.
Moreover, E*TRADE’s net new retail assets came in at $0.7 billion compared with $1.4 billion reported in the previous month.
At the end of October, E*TRADE’s customer security holdings were $291.6 billion, up from the $284.7 billion in September. The company’s brokerage-related cash came in at $66.1 billion compared with the previous month’s $65 billion. In addition, bank-related cash and deposits for the company totaled $10 billion, up from the $9.6 billion recorded in September.
Peer Performance
Interactive Brokers Group, Inc. (IBKR - Free Report) has released its Electronic Brokerage segment’s performance metrics for October 2019. The segment, which deals with the clearance and settlement of trades for individual and institutional clients globally, reported a decrease in DARTs.
Among others, LPL Financial Holdings Inc. (LPLA - Free Report) and Charles Schwab’s (SCHW - Free Report) are expected to release its October activity report this week.
Our Viewpoint
Though the uncertain macroeconomic environment might lead to lesser trading activities, growth in DARTs and new brokerage accounts will prove beneficial for the company.
The company’s shares have lost around 15.4% over the past year compared with 1.8% decline recorded by the industry.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
E*TRADE (ETFC) Reports 9% Sequential Growth in October DARTs
E*TRADE Financial has reported a sequential rise in Daily Average Revenue Trades (DARTs) for October. According to its monthly market activity, the company’s DARTs came in at 290,578, up 9% from the previous month, but down 1% year over year. Notably, derivatives comprised 36% of DARTs.
Broker performance is generally measured through DARTs that represent the number of trades from which brokers can expect commission or fees. The rise in DARTs largely reflects investors’ willingness to invest in equity markets.
At the end of October 2019, E*TRADE’s total number of accounts were approximately 7.2 million, comprising about 5.1 million retail accounts, 1.9 million corporate services accounts, and 0.2 million advisor services accounts.
E*TRADE’s total accounts included 13,535 net reductions for October. Total brokerage accounts highlight the company’s ability to gain and retain customers who trade and invest.
Moreover, E*TRADE’s net new retail assets came in at $0.7 billion compared with $1.4 billion reported in the previous month.
At the end of October, E*TRADE’s customer security holdings were $291.6 billion, up from the $284.7 billion in September. The company’s brokerage-related cash came in at $66.1 billion compared with the previous month’s $65 billion. In addition, bank-related cash and deposits for the company totaled $10 billion, up from the $9.6 billion recorded in September.
Peer Performance
Interactive Brokers Group, Inc. (IBKR - Free Report) has released its Electronic Brokerage segment’s performance metrics for October 2019. The segment, which deals with the clearance and settlement of trades for individual and institutional clients globally, reported a decrease in DARTs.
Among others, LPL Financial Holdings Inc. (LPLA - Free Report) and Charles Schwab’s (SCHW - Free Report) are expected to release its October activity report this week.
Our Viewpoint
Though the uncertain macroeconomic environment might lead to lesser trading activities, growth in DARTs and new brokerage accounts will prove beneficial for the company.
E*TRADE currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The company’s shares have lost around 15.4% over the past year compared with 1.8% decline recorded by the industry.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>